Grant: CIHR Fellowship
University of Toronto
$135,000.00
A zebrafish-based screening strategy for the identification of tissue-selective PPARgamma agonists.
FY 2011-12
Summary
It is estimated that nearly 3 million Canadians suffer from the complications of diabetes. Among these, the majority suffer from type 2 diabetes mellitus, which is characterized by the failure of cells to take up glucose in response to insulin. These patients are generally treated with a combination of lifestyle modifications and various oral anti-diabetic medications. Drugs in the thiazolidinedione family for example, increase the ability of cells to take up glucose in response to insulin and are an effective means of lowering blood sugar. Unfortunately, recent evidence has linked this class of drugs to some serious side effects including cardiovascular complications and an increased risk of bone fractures, thereby limiting their long-term clinical utility. It has been known for some time that thiazolidinediones increase insulin sensitivity by activating a molecular switch known as PPARgamma inside of cells. However, the mechanism underlying many of the side effects remains elusive. I hypothesize that the inappropriate activation of PPARgamma in a subset of tissues is a major contributor to the side effects of thiazolidinedione treatment and that the development of drugs capable of selectively activating PPARgamma only in tissues where it is required will generate a safer class of insulin sensitizing medications. In order to accomplish this I will utilize a genetically modified zebrafish model in which all cells have been engineered to produce a fluorescent marker upon activation of PPARgamma. This model will allow me to treat large numbers of zebrafish with a large number of prospective medications and easily identify drugs that promote tissue selective activation of PPARgamma. All drugs exhibiting a high degree of tissue selectivity will subsequently be tested for insulin sensitizing effects in a mouse model of diabetes. Ultimately, this research will advance our understanding of the role of PPARgamma in diabetes, paving the way for improved anti-diabetic drugs.
Department
Program
CIHR Fellowship
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
255093
Name
Long Micheal A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
A zebrafish-based screening strategy for the identification of tissue-selective PPARgamma agonists.
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Diabetes; Drug Screening; Nuclear Receptors; Proteomics; Zebrafish
Abstract
It is estimated that nearly 3 million Canadians suffer from the complications of diabetes. Among these, the majority suffer from type 2 diabetes mellitus, which is characterized by the failure of cells to take up glucose in response to insulin. These patients are generally treated with a combination of lifestyle modifications and various oral anti-diabetic medications. Drugs in the thiazolidinedione family for example, increase the ability of cells to take up glucose in response to insulin and are an effective means of lowering blood sugar. Unfortunately, recent evidence has linked this class of drugs to some serious side effects including cardiovascular complications and an increased risk of bone fractures, thereby limiting their long-term clinical utility. It has been known for some time that thiazolidinediones increase insulin sensitivity by activating a molecular switch known as PPARgamma inside of cells. However, the mechanism underlying many of the side effects remains elusive. I hypothesize that the inappropriate activation of PPARgamma in a subset of tissues is a major contributor to the side effects of thiazolidinedione treatment and that the development of drugs capable of selectively activating PPARgamma only in tissues where it is required will generate a safer class of insulin sensitizing medications. In order to accomplish this I will utilize a genetically modified zebrafish model in which all cells have been engineered to produce a fluorescent marker upon activation of PPARgamma. This model will allow me to treat large numbers of zebrafish with a large number of prospective medications and easily identify drugs that promote tissue selective activation of PPARgamma. All drugs exhibiting a high degree of tissue selectivity will subsequently be tested for insulin sensitizing effects in a mouse model of diabetes. Ultimately, this research will advance our understanding of the role of PPARgamma in diabetes, paving the way for improved anti-diabetic drugs.
Competitiondate
201202
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Long, Micheal A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~